Venus Remedies has entered into an in-licensing deal with Jiangsu Provincial Institute of Microbiology, China for the exclusive manufacturing and marketing rights for the latest generation amino-glycoside formulation for the Indian market.According to a release issued by Venus to the BSE today, the patented product is the safest among existing amino-glycoside available worldwide. "It is a technology breakthrough with the least reported nephro-toxicity with 2400% lesser adverse drug reactions as compared to Gentamycin. The product has worldwide patent and the vompany has got the exclusive manufacturing and marketing rights for India for 10 years," the release added.The Phase-III, multi-centre clinical trials process has been initiated, and commercial launch is expected in Q32008 after the necessary regulatory approvals. The product has a market worth Rs 600 crore and is growing at 8% per annum, the release added.
